Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic &

Status Recruiting

Clinical Trial Summary

Hyponatremia is the most common electrolyte derangement occurring in hospitalized patients. It is usually classified as hypovolemic, euvolemic or hypervolemic. The most common aetiology of euvolemic hyponatremia is the syndrome of inappropriate antidiuresis (SIAD). Hypervolemic hyponatremia is common in patients with congestive heart failure (CHF) (10-27%) and liver cirrhosis (up to approximately 50%). In SIAD, the regulation of arginine vasopressin (AVP) secretion is impaired which leads to free water retention. In CHF and liver cirrhosis, the effective arterial blood volume is decreased leading to non-osmotic baroreceptor mediated AVP release and consecutive free water retention. Current treatments of euvolemic and hypervolemic hyponatremia, including the most used treatment fluid restriction, are of limited efficacy. Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitors reduce glucose reabsorption in the proximal tubule, resulting in glucosuria and consecutive osmotic diuresis. A placebo-controlled randomized trial of our group has shown that a short-term, i.e. a 4-days administration of the SGLT2 inhibitor empagliflozin (Jardiance)® in addition to fluid restriction was effective in increasing the serum sodium concentration in 87 patients with SIAD-induced hyponatremia. The effect of empagliflozin (Jardiance)® without additional fluid restriction is however not yet known. Large randomized controlled trials have shown that SGLT2 inhibitors reduced hospitalization for heart failure in patients with, and more recently without type 2 diabetes. No studies have investigated the effect of SGLT2 inhibitors in hypervolemic hyponatremia. To evaluate the effect of empagliflozin (Jardiance)® in eu- and hypervolemic hyponatremia, a randomized placebo-controlled study is needed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04447911
Study type	Interventional
Source	University Hospital, Basel, Switzerland
Contact	Mirjam Christ-Crain, Prof
Phone	+41 61 328 70 80
Email	Mirjam.Christ-Crain@usb.ch
Status	Recruiting
Phase	Phase 4
Start date	February 4, 2021
Completion date	February 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04510090` - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus	Phase 1
Completed	`NCT02546037` - Clotting With Different Dialyzer Membranes
Recruiting	`NCT02545920` - To Assess Ear Blood Flow During Dialysis
Completed	`NCT02134314` - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/Phase 2
Recruiting	`NCT01912001` - Virtual Ward for Home Dialysis	N/A
Completed	`NCT00986947` - Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates	Phase 2
Completed	`NCT01158742` - Live Kidney Donor Study -Renal Function Study	N/A
Completed	`NCT00765661` - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients	Phase 2
Withdrawn	`NCT00807274` - Renal Function in Adults With Congenital Heart Disease.	N/A
Completed	`NCT00369382` - Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients	Phase 4
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Enrolling by invitation	`NCT05324878` - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Completed	`NCT05272800` - BIS-guided Fluid Management in HD Patients	N/A
Completed	`NCT03836508` - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis	N/A
Completed	`NCT01756508` - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury	Phase 2
Completed	`NCT03723668` - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting	`NCT04277377` - Nanoparticle for DSA Removal
Terminated	`NCT00450333` - Dynepo Infrequent Dosing Study	Phase 3
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Recruiting	`NCT04714853` - Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia — EMPOWER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms